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Endothelin is a novel endothelium-derived vasoactive peptide with 
potent vasoconstrictor action in the coronary bed; however, its 
possible contribution to myocardial ischemia and infarction is not 
known. Plasma endothelin-l concentration was measured with use 
of a radioimmunoassay in serial venous samples from 22 patients 
over a 72 h period after acute myocardial infarction (14 patients 
with uncomplicated infarction [group I] and 8 patients with 
hemodynamic or ischemic sequelae [group II]). Twenty-two nor-
mal subjects and seven patients with stable angina served as the 
control subjects. 
Endothelin-l levels in patients with stable coronary disease 
were not different from those of normal subjects (0.62 ± 0.56 and 
0.76 ± 0.38 pg/ml, respectively). In group I, plasma levels of 
endothelin-l rose sharply after myocardial infarction, reaching a 
peak of 4.95 ± 0.78 pg/m1 at 6 h after the onset of chest pain (p < 
0.05 compared with values in control subjects) and returning 
rapidly toward the normal range by 24 h. Patients with compli-
cated infarction (group II) demonstrated a similar rapid increase 
in plasma endothelin-l to a peak value of 8.29 ± 1.95 pg/ml; 
Endothelin, a vasoactive peptide recently isolated from the 
supernatant of endothelial cells in culture (1), is a potent 
constrictor of isolated coronary arteries from animals (1,2) 
and humans (3-5). Endothelin produces marked increases in 
coronary vascular resistance in the isolated perfused heart 
(6-8) or when infused in vivo (9-11) and can lead to 
ischemia and death (11). Therefore, it has been suggested 
(11) that endogenous production of endothelin might contrib-
ute to myocardial ischemia and infarction in humans. 
However, little is known about the local production and 
release of endothelin in animals and humans. Stimuli that 
damage endothelium have been reported (12-14) to greatly 
increase endothelin levels. Recently, we (15) developed a 
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however, plasma endothelin-l remained elevated in these patients, 
becoming significantly different from values in group I at 48 and 
72 h. 
There was no correlation between peak increases in creatine 
kinase and peak endothelin-l in either group, suggesting that the 
stimulus for elevation of endothelin-l was not myocardial necrosis 
itself. Furthermore, left ventricular ejection fraction did not 
correlate with the increase in endothelin-l in group I patients, 
whereas there was a significant inverse relation between ventric-
ular function and plasma endothelin-l in group II. 
Therefore, the rapid increase in plasma endothelin-l associ-
ated with the onset of infarction suggests that this peptide may 
provide a marker of endothelial perturbation in the early phase of 
coronary ischemia or even contribute to alterations in myocardial 
perfusion. The sustained increase in plasma endothelin-l in pa-
tients demonstrating complications of myocardial infarction might 
reflect continuing ischemia or marked depression in ventricular 
function in these patients. 
(J Am CoU CardioI1991;18:38-43) 
sensItIve and specific assay for measuring endothelin in 
plasma and reported that circulating levels were markedly 
elevated in patients with cardiogenic shock. Because cardio-
genic shock is a complex pathophysiologic state character-
ized by systemic hypoperfusion and multiorgan dysfunction, 
it is difficult to attribute the observed increases in circulating 
endothelin to an abnormality of anyone vascular bed. 
The aim of the present investigation was to determine 
whether myocardial infarction itself would result in elevated 
plasma endothelin levels. Therefore, circulating endothelin 
concentrations were measured in patients with acute myo-
cardial infarction of varying severity, both with and without 
hemodynamic compromise or other complications. Frequent 
plasma samples were obtained as soon as possible from the 
onset of infarction to define the time course of release during 
myocardial infarction and the potential contribution of en-
dothelin to the early phase of cardiac ischemia and injury. 
Methods 
Study patients. Twenty-two patients presenting with pro-
longed chest pain were diagnosed as having acute myocar-
dial infarction by evolving electrocardiographic (ECG) ab-
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normalities, an increase in serum creatine kinase (CK) 
greater than twice the upper limit of normal and a significant 
increase in the CK MB isoenzyme level. When possible, 
venous blood samples for endothelin measurement were 
obtained as early as 2 h after the onset of chest pain and 
again at 4, 6, 8, 12, 24,48 and 72 h. Samples were also drawn 
for CK at 4, 8, 12, 24, 48 and 72 h. Patients were admitted to 
the coronary care unit at the Royal Victoria Hospital and 
monitored closely for complications of myocardial infarc-
tion. 
Patients were classified into two groups: group I showed 
no evidence of hemodynamic or ischemic complications, 
whereas group II had evidence of hemodynamic compromise 
defined as hypotension (blood pressure <90 mm Hg systolic 
unresponsive to infusion of saline solution), heart failure 
(rales more than half way up the chest with radiographic 
evidence of pulmonary edema and, when this measure-
ment was available, mean pulmonary artery wedge pressure 
> 18 mm Hg) or recurrent myocardial ischemia (recurrence 
of chest pain with ECG evidence of new ischemia or a 
second CK increase, or both). Transient ventricular arrhyth-
mias alone during the study period were not considered 
sufficient to classify patients into group II. 
Plasma endothelin was measured in 22 normal subjects 
and 7 patients with stable coronary artery disease undergo-
ing cardiac catheterization. This study was performed in 
accordance with the guidelines of the Food and Drug Ad-
ministration and the Health Protection Branch and was 
approved by the Royal Victoria Hospital Institutional Re-
view Board (Ethics Committee) on October 2, 1989. 
Measurement of endothelin and cardiac enzymes. Venous 
blood was collected in ethylenediamine tetraacetic acid 
(EDT A)-containing tubes and centrifuged at 1,800 g for 
20 min at 4°C. Plasma was stored at -80°C for $1 week. 
Under these conditions, no decrease in measured endothelin 
plasma concentration was observed. Plasma endothelin was 
measured with use of a modification of the previously 
described radioimmunoassay (15). In brief, samples were 
loaded onto SepPak CI8 cartridges (Waters), activated with 
methanol, 8 M urea and water and eluted with methanol, 
yielding a recovery of 75 ± 3.3%. Samples and standards 
(endothelin-l, Peninsula Laboratories) were reconstituted in 
assay buffer and incubated for 24 h with rabbit anti-
endothelin-l serum (Peninsula Laboratories) at 4°C. The 
addition of approximately 4,000 cpm of iodine-125 endothe-
lin-l (Peninsula Laboratories) was followed by a second 24 h 
incubation, and bound and free radioligand were separated 
using the second antibody method. Bound radioactivity data 
were evaluated after logitllog transformation and the immu-
noreactive endothelin-l data were presented after correction 
for recovery. 
The antibody exhibited a cross-reactivity of 10% with 
human "big" endothelin-l and 5% with endothelin-3, but no 
cross-reactivity with unrelated peptides (namely, atrial natri-
uretic factor 1-28, brain natriuretic peptide, vasopressin, 
angiotensin I and 11). The standard curve, defined by the 
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equation logit B/Bo = 1.74 - 2.02 log pg endothelin-l (where 
B = bound radioactivity in the presence of standard or 
sample, and Bo = bound radioactivity at zero concentration 
of endothelin-l), was very stable, with a midpoint (IC50) of 
7.23 ± 0.58 pg/tube. The limit of detection, defined as the 
least amount of immunoreactive endothelin-l distinguishable 
from zero at 95% confidence, was 0.12 pg/tube. The intra-
and interassay coefficients of variation were 9% and 12%, 
respectively. Serial dilutions of the plasma extract inhibited 
binding of radioligand in parallel with the standard curve. 
High pressure liquid chromatography of plasma extract 
demonstrated a dominant peak of immunoreactive endothe-
lin-l coeluting with synthetic endothelin-l. 
Creatine kinase was measured in venous serum with use 
of an automated enzyme analyzer (Technicon RA 1000) and 
determination of CK MB isoenzyme was performed using 
the Sigma kit (RA 1000). Left ventricular ejection fraction 
was determined in all patients by radionuclide gated angiog-
raphy. 
Statistical analysis. Values are presented as mean 
values ± SEM. Significance of differences was determined 
using Student's t test. A p value < 0.05 was considered 
significant. 
Results 
Patient characteristics (Tables 1 and 2). Of the 22 patients 
with acute myocardial infarction, 14 (11 men and 3 women) 
met the criteria for group I and 8 (5 men and 3 women) for 
group II (Table 2). Patients in group II were significantly 
older than those in group I (66 ± 3 and 55 ± 3 years, 
respectively, p < 0.05) and demonstrated a higher incidence 
of anterior myocardial infarction (75% vs. 57%). Left ven-
tricular ejection fraction was lower in group II than in group 
I (33 ± 5% and 42 ± 3%, respectively), but this difference 
was not significant. Thrombolytic therapy was administered 
to eight patients (57%) in group I and three (37%) in group II. 
Control endothelin·1 levels. Mean plasma endothelin-l 
concentration in 22 normal volunteers (mean age 33 ± 5 
years) was 0.76 ± 0.38 pg/ml, with an upper limit of normal 
defined as the mean + 2 SD of 1.52 pg/ml. Seven patients 
(mean age 55 ± 8 years) undergoing cardiac catheterization 
for stable coronary artery disease constituted a second 
control group. These patients with stable exertional angina 
had a mean plasma endothelin level of 0.62 ± 0.56 pg/ml (not 
different from normal). 
Time course of endothelin·1 levels after uncomplicated 
myocardial infarction (Fig. I). Plasma endothelin-l levels 
increased sharply after myocardial infarction from a 
value not significantly different from normal in four patients 
at 2 h from the onset of chest pain to a peak value of 4.95 ± 
0.78 pg/ml at 6 h (p < 0.05). Thereafter, plasma immunore-
active endothelin-l decreased rapidly to 1.75 ± 0.38 pg/ml by 
24 h, remaining slightly above the normal range until 72 h. In 
contrast to the increase in CK, the peak increase in immu-
noreactive endothelin-l occurred substantially earlier (6 vs. 
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Table 1. Clinical Data in 14 Patients With Uncomplicated Myocardial Infarction (group I) 
Site of Age (yr)1 Killip LVEF Peak ET Peak CK 
Pt. No. MI Gender Thrombolysis Class (%) (pg/ml) (Ulliter) 
1 Inf 63/M No 45 6.36 1,285 
2 Inf 441M STR 40 4.8 4,990 
3 Inf 481M STR 55 5.51 240 
4 Ant 401M TPA 30 3.51 1,455 
5 Ant 531M STR I 40 3.89 2,004 
6 Ant 471M No I 30 2.24 1,680 
7 Ant 611M No II 45 8.91 5,355 
8 Ant 77/F No II 35 4.6 2,559 
9 Ant 561M STR 55 2.6 1,548 
10 Ant 531M STR 21 3.28 2,382 
11 Inf 68/F No 53 7.13 1,269 
12 Ant 60/F No II 38 1.89 1,034 
13 Inf 481M STR I 45 9.67 3,536 
14 Inf 541M STR I 50 7.92 3,048 
Mean 55.14 41.57 5.17 2,313.21 
± SEM 2.57 2.62 0.67 380.78 
Ant = anterior; CK = creatine kinase; ET = endothelin-1; F = female; Inf = inferior; LVEF = left ventricular ejection fraction; M = male; MI = myocardial 
infarction; Pt. = patient; STR = streptokinase; TPA = tissue plasminogen activator. 
12 to 24 h) and was more strongly associated with onset of 
infarction. 
Endothelin-l in complicated versus uncomplicated infarc-
tion (Fig. 2 to 4). Peak levels of immunoreactive endothe-
lin-I tended to be greater in group II patients with compli-
cated myocardial infarction than in group I patients with 
uncomplicated myocardial infarction (Tables 1 and 2, Fig. 2). 
Moreover, plasma immunoreactive endothelin-l remained 
elevated in patients exhibiting complications in contrast to 
the rapid return toward the normal range observed in group 
I patients, becoming significantly different at 48 and 72 h. 
However, in neither group of patients was there a correlation 
between peak CK and peak endothelin-l level (Fig. 3). The 
best example of this dissociation was provided by the patient 
with the smallest increase in CK (Patient 3), who demon-
strated an increase in plasma immunoreactive endothelin-l 
almost identical to the mean level for group I. Subsequent 
angiography showed a severely stenotic proximal right cor-
onary artery subtending a large distal bed and near normal 
left ventricular function with only mild inferior hypokinesia. 
Similarly, there was no correlation between peak endothe-
lin-l level and left ventricular ejection fraction in patients 
with uncomplicated infarction (Fig. 4A). However, patients 
with complicated infarction demonstrated a significant in-
verse relation, with the highest plasma endothelin-l levels 
found in patients with the lowest ejection fraction (Fig. 4B). 
Discussion 
Plasma endothelin-l in uncomplicated versus complicated 
myocardial infarction. The present study demonstrates that 
levels of immunoreactive endothelin-l in the venous blood 
were markedly elevated after myocardial infarction, even in 
the absence of hemodynamic sequelae. In contrast to previ-
ous studies (16,17), in this study plasma samples were 
obtained within the early hours after the onset of chest pain, 
and therefore the timing of the peak increase in endothelin-l 
after myocardial infarction could be defined. In patients with 
Table 2. Clinical Data in Eight Patients With Complicated Myocardial Infarction (group II) 
Site of Age (yr)1 Killip LVEF Peak ET Peak CK 
Pt. No. MI Gender Thrombolysis Class (%) (pg/ml) (Ulliter) Complication 
15 Ant 621M No III 48 4.63 1,460 Pulmonary edema 
16 Inf 651M STR 50 5.56 921 RV infarction 
17 Ant 80/F No III 25 10.6 2,735 Pulmonary edema 
18 Ant 751M No III 25 4.49 408 Pulmonary edema 
19 Inf 561M STR I 45 6.31 855 Recurrent ischemia 
20 Ant 68/F No IV 14 20.8 944 Cardiogenic shock 
21 Ant 651M No IV 20 9.05 353 Cardiogenic shock 
22 Ant 551F STR 40 4.92 2,937 Recurrent ischemia 
Mean 65.75 33.38 8.29 1,326.63 
± SEM 2.85 4.62 1.95 328.82 
RV = right ventricular; other abbreviations as in Table I. 
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Figure 1. Time course of plasma immunoreactive endothelin-l 
(irET-I) (left ordinate, open circles) and serum creatine kinase (CK) 
(right ordinate, open squares) for patients in group I. The time in 
hours after the onset of myocardial infarction (post MI) appears on 
the abscissa. The dashed line indicates the mean value of plasma 
immunoreactive endothelin-l in normal subjects. The shaded area 
indicates normal range (mean ± 2 SD). * = p < 0.05 compared with 
values in normal subjects; + = P < 0.05 compared with the 2 h 
value. 
uncomplicated infarction (group I), the increase in plasma 
endothelin-l was strongly associated with the onset of the 
ischemic event (Fig. I), reaching a maximum by 6 h com-
pared with a maximal increase in CK occurring between 16 
to 24 h and rapidly returning toward the normal range by 24 
to 72 h. In contrast, in patients with complicated infarction 
(group II), endothelin-llevels remained elevated, becoming 
significantly greater than in group I patients at 48 and 72 h. 
Effect of endothelin·l on coronary vasomotor tone. 
Whether these observed increases in plasma endothelin-l 
could produce coronary vasoconstriction and further com-
Figure 2. Time course of plasma immunoreactive endothelin-l 
(irET-I) (ordinate) in patients after uncomplicated (group I) and 
complicated (group II) myocardial infarction (MI). The time in hours 
after (post) the onset of myocardial infarction appears on the 
abscissa. The shaded area indicates the normal range. * = p < 0.05 
compared with values in normal subjects; + = P < 0.05 compared 
with values in group I. 
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Figure 3. Peak elevation in creatine kinase (CK) (ordinate) is plotted 
against peak increase in immunoreactive endothelin-l (irET-I) (ab· 
scissa) for patients with uncomplicated (group I) (closed circles) and 
complicated (group II) (closed squares) myocardial infarction. 
promise coronary blood flow in patients after myocardial 
infarction is a crucial question. Even the highest plasma 
level measured (that is, 20 pg/ml [8 pmollliterD is probably 
below the threshold estimated to induce vasoconstriction in 
human arteries in vitro (3-5,18,19). However, endothelin-l 
concentrations of approximately 10 pmollliter were found to 
produce a significant vasopressor response during infusion 
of the synthetic peptide in humans (20). In addition, the 
susceptibility ofthe coronary circulation to the vasoconstric-
tor action of endothelin may be greatly potentiated by 
damage to the coronary endothelium (7), particularly after an 
ischemic insult (21). Therefore, even relatively low circulat-
ing concentrations of endothelin may markedly alter coro-
nary vasomotor tone in areas of ischemic damage associated 
with myocardial infarction. 
Stimuli that lead to release of endothelin from coronary 
vasculature. Endothelin-l is a product of vascular endothe-
lium (1) and likely achieves its highest concentration and 
greatest action at the local vascular site of its release (1,22). 
Thus, the concentration of endothelin within the coronary 
vasculature may be considerably higher than the levels 
measured in the circulating blood and well within the range 
of biologic action. The mechanism whereby the release of 
endothelin-l is stimulated after myocardial infarction r~­
mains to be determined. In vitro studies (1,23-25) have 
shown that both hypoxia and thrombin can induce the 
release of endothelin from endothelial cells. Activation of 
the coagulation cascade at the site of a complex coronary 
stenosis with generation of thrombin is thought to initiate 
occlusive thrombosis (26). In addition, decreased delivery of 
oxygen leads to regional hypoxia and ischemia. Thus, these 
and other stimuli could induce the release of endothelin from 
the coronary vasculature after acute coronary occlusion. 
Indeed, myocardial infarction in animal models (27) has been 
shown to result in increased endothelin levels in the heart, 
possibly contributing to infarct extension, and ischemia! 
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Figure 4. Left ventricular ejection fraction (L VEF) 
(ordinate) is plotted against immunoreactive endothe-
lin-l (irET-!) (abscissa) for patients with uncompli-
cated infarction (group I) (panel A) and patients with 
hemodynamic or ischemic complications (group II) 
(panel B). 
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reperfusion has been reported (28) to increase endothelin 
binding sites in cardiac membranes. 
Correlation of endothelin·l and CK levels. In the present 
study, there was no correlation between peak elevations in 
plasma CK and immunoreactive endothelin-1 after myocar-
dial infarction, suggesting that increase in the latter may not 
be related to myocardiai necrosis itself, but to other vascular 
events associated with infarction, such as the degree of 
coronary ischemia. Plasma endothelin may be a marker 
of endothelial cell perturbation (22) that precedes frank 
necrosis or occurs in areas adjacent to the zone of infarc-
tion. This is in agreement with observations in individual 
patients that substantial increases in circulating endothelin-1 
were found even in association with only a small infarct 
as determined by cardiac enzyme and functional criteria 
(Table O. 
Mechanism of sustained increases in plasma endothelin·l. 
Patients with complicated myocardial infarction demon-
strated a rapid increase in plasma immunoreactive endothe-
lin-1 similar to that in the patients with uncomplicated 
infarction (Fig. 2). However, in contrast to the group with 
uncomplicated infarction, this increase was sustained over 
the study period rather than being transient. This might 
explain the more prolonged elevation in plasma endothelin 
described in earlier studies (16,17) that did not differentiate 
between these two groups. Sustained increases in endothelin 
might reflect continued ischemia due to incomplete infarc-
tion or infarct extension in some patients (Table 1). How-
ever, it is likely that the mechanism of elevated endothelin 
was multifactorial in patients demonstrating hemodynamic 
compromise and may have included systemic hypoperfusion 
and multiorgan ischemia (15), the effect of circulating 
catecholamines or pressor agents (for example, norepineph-
rine) (1) and decreased pulmonary (29-31) or renal (32) 
clearance as a result of lung congestion or decreased renal 
blood flow. 
Correlation with left ventricular function. In group I 
patients, there was no correlation between left ventricular 
function and peak endothelin levels (Fig. 4A), a finding 
consistent with the concept that in the absence of hemody-
namic complications, the extent of ischemia rather than 
the actual area of necrosis might be a crucial determinant 
of endothelin release. In contrast, after complicated infarc-
tion, the highest levels of endothelin-1 were observed in 
patients with the lowest ejection fraction (group II) (Fig. 
4B). This again suggests that depressed myocardial per-
formance contributed importantly to the more marked 
and sustained elevations in endothelin-1 observed in this 
group. Despite the development of hemodynamic complica-
tions in many of the group II patients, the peak CK increase 
tended to be lower than in group I patients (Tables 1 and 2). 
This apparent discrepancy between the size of infarction 
by enzyme criteria and its hemodynamic consequences 
can be explained if preexisting depression of left ventricular 
function made some patients unable to tolerate even 
small areas of further damage. In addition, a higher propor-
tion of group I patients received thrombolytic therapy; thus 
in some patients an early "washout" on reperfusion might 
have raised the peak serum CK level in relation to infarct 
size. 
Conclusions. Plasma endothelin levels increase signifi-
cantly after uncomplicated acute myocardial infarction and 
might provide a marker of endothelial cell perturbation in the 
early phase of myocardial ischemia. Because endothelin 
levels in plasma are near maximal at a time when CK is 
barely elevated, this could assist in the diagnosis of impor-
tant myocardial ischemia soon after its onset. In addition, 
plasma concentrations of endothelin might also reflect ab-
normalities of systemic perfusion in states of markedly 
depressed cardiac performance. The potential role of this 
potent vasoconstrictor peptide in the pathophysiology of 
myocardial infarction and its hemodynamic complications 
are areas of important future research. 
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